Xennials Therapeutics Australia Pty Ltd, in collaboration with PinotBio Inc., announces the enrollment of First patient in to the Phase 1/2 study of NTX-301 as a single agent and in combination with Standard of Care in selected solid tumors

by | Sep 2, 2021 | Latest News

Sydney, Australia, CHICAGO, Ill USA and Gyeonggi-do, South Korea. September 02, 2021. Today, Xennials Therapeutics Australia Pty, Ltd., subsidiary of Xennials Therapeutics, Inc., a clinical stage biotechnology company dedicated to the development of transformative...